{
    "id": 3078,
    "name": "grade III astrocytoma",
    "source": "DOID",
    "definition": "An astrocytoma that is characterized by cells with regular, round to oval nuclei. [url:http\\://en.wikipedia.org/wiki/Anaplastic_astrocytoma, url:http\\://www.abta.org/brain-tumor-information/types-of-tumors/astrocytoma.html, url:http\\://www.cancer.gov/dictionary?CdrID=45591]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3078",
    "evidence": [
        {
            "id": 849,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, long-term treatment with Vidaza (azacitidine) resulted in increased cellular differentiation, decreased proliferation, and tumor regression in a patient-derived xenograft (PDX) model of anaplastic astrocytoma harboring IDH1 R132H (PMID: 24077805).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 651,
                "therapyName": "Azacitidine",
                "synonyms": null
            },
            "indication": {
                "id": 3078,
                "name": "grade III astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 493,
                    "pubMedId": 24077805,
                    "title": "5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24077805"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13380,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "IDH1 mutations aid in the diagnosis of grade III astrocytomas (NCCN.org).",
            "molecularProfile": {
                "id": 1781,
                "profileName": "IDH1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3078,
                "name": "grade III astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13390,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "IDH2 mutations aid in the diagnosis of grade III astrocytomas (NCCN.org).",
            "molecularProfile": {
                "id": 5912,
                "profileName": "IDH2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3078,
                "name": "grade III astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19915,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Trabedersen (AP 12009) treatment in patients with recurrent or refractory high-grade glioma (including grade IV glioblastoma multiforme or grade III astrocytoma) resulted in responses in 19 (3 complete and 16 partial responses) and stable disease for at least 6 months in 7 of 77 patients in the efficacy population, and a median progression-free survival of 86 days and median overall survival of 432 days (PMID: 31795071; NCT00431561).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2705,
                "therapyName": "Trabedersen",
                "synonyms": null
            },
            "indication": {
                "id": 3078,
                "name": "grade III astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17587,
                    "pubMedId": 31795071,
                    "title": "Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGF\u03b22-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31795071"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02052778",
            "title": "A Study of TAS-120 in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1053,
                    "therapyName": "Futibatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02800486",
            "title": "Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03128047",
            "title": "HUMC 1612: Optune NovoTTF-200A System",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2115,
                    "therapyName": "Bevacizumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03657576",
            "title": "Trial of C134 in Patients With Recurrent GBM (C134-HSV-1)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9748,
                    "therapyName": "C134-HSV-1",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03893487",
            "title": "Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 709,
                    "therapyName": "CUDC-907",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03973918",
            "title": "Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04254419",
            "title": "Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT04295759",
            "title": "INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 6876,
                    "therapyName": "INCB7839",
                    "synonyms": null
                }
            ]
        }
    ]
}